Get the Stockscreener App
19.44
0.66%
-0.13
Amneal Pharmaceuticals Inc stock is traded at $19.44, with a volume of 629.42K.
It is down -0.66% in the last 24 hours and up +12.89% over the past month.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
See More
Previous Close:
$19.57
Open:
$19.49
24h Volume:
629.42K
Relative Volume:
0.17
Market Cap:
$6.77B
Revenue:
$3.05B
Net Income/Loss:
$181.32M
P/E Ratio:
52.12
EPS:
0.373
Net Cash Flow:
$186.11M
1W Performance:
-1.07%
1M Performance:
+12.89%
6M Performance:
+48.17%
1Y Performance:
+100.00%
1-Day Range:
$19.34
$19.93
1-Week Range:
$18.97
$20.28
52-Week Range:
$9.56
$21.18
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
19.44 | 6.77B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
18.93 | 60.49B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.66 | 48.59B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.65 | 42.44B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.67 | 31.27B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
538.04 | 23.08B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-09-26 | Initiated | Leerink Partners | Outperform |
| Apr-17-26 | Initiated | UBS | Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com UK
Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust - Kalkine Media
Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees - Stock Titan
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - goSkagit
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - postregister.com
Amneal Pharmaceuticals, Inc.Class A Common Stock (NQ: AMRX - The Chronicle-Journal
Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target - marketscreener.com
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
ZLAB Stock Price, Quote & News - Syfe
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Amneal builds end-to-end biosimilars capacity in the U.S. - chaindrugreview.com
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - sahmcapital.com
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - vinanet.vn
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
Amneal Pharmaceuticals Insider Sold Shares Worth $2,563,517, According to a Recent SEC Filing - Yahoo Finance
Amneal Pharmaceuticals Insider Sold Shares Worth $3,771,050, According to a Recent SEC Filing - Yahoo Finance
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amneal Pharmaceuticals Inc Stock (AMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kiely John | Director |
Aug 13 '26 |
Sale |
17.64 |
50,000 |
882,000 |
210,252 |
| JOHN KIELY | Director |
Aug 13 '26 |
Proposed Sale |
17.59 |
50,000 |
879,714 |
0 |
| NIKITA SHAH | Officer |
Aug 12 '26 |
Proposed Sale |
17.47 |
146,403 |
2,556,975 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 12 '26 |
Sale |
17.40 |
210,000 |
3,654,000 |
35,171 |
| Shah Nikita | Executive Vice President |
Aug 12 '26 |
Sale |
17.51 |
146,403 |
2,563,517 |
253,390 |
| BUCHI J KEVIN | Director |
Aug 11 '26 |
Proposed Sale |
17.31 |
168,573 |
2,917,998 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 11 '26 |
Sale |
17.70 |
6,613 |
117,050 |
245,171 |
| JASON DALY | OFFICER |
Aug 11 '26 |
Proposed Sale |
17.36 |
210,000 |
3,646,285 |
0 |
| Autor Deborah M. | Director |
May 11 '26 |
Sale |
12.94 |
34,819 |
450,558 |
93,660 |
| DEBORAH AUTOR | DIRECTOR |
May 11 '26 |
Proposed Sale |
12.94 |
34,819 |
450,416 |
0 |
0.10%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):